- Shanghai-based MicuRx's MRX-5 receives FDA Orphan Drug Designation for treating non-tuberculous mycobacteria (NTM) infections.
- MRX-5 shows promise with strong antibacterial activity, safety, and suitability for chronic treatment, addressing major NTM treatment gaps.
Shanghai-based MicuRx Pharmaceutical Co., Ltd. has announced that its experimental drug, MRX-5, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). The designation applies to MRX-5's use in treating non-tuberculous mycobacteria (NTM) infections, a growing public health concern worldwide.
NTM infections, caused by a group of environmental mycobacteria, have been increasingly reported over the years, posing significant treatment challenges. Current therapies are often hampered by issues such as limited efficacy, drug resistance, and adverse effects. MRX-5, a novel benzoxazole antibiotic developed by MicuRx, aims to address these shortcomings.
According to the company, MRX-5 has shown promising antibacterial activity against various NTM strains in both preclinical and early human studies. The drug also boasts favorable safety and pharmacokinetic profiles, low resistance potential, and high oral bioavailability, making it particularly suitable for chronic treatment.
The FDA's ODD program is designed to encourage the development of drugs targeting rare diseases affecting fewer than 200,000 people in the United States. The designation provides incentives to developers, including tax credits, fee waivers for certain clinical trials, and market exclusivity for seven years upon approval. These benefits are expected to accelerate the clinical development and potential commercialization of MRX-5.
While the ODD is a significant milestone, MicuRx emphasized its commitment to advancing MRX-5's development. The company aims to refine oral treatment regimens and deliver safer, more effective therapies for patients battling NTM infections.
Edited by Harshajit Sarmah
